Screener
Medline, Inc. MDLN Embedded derivatives gain (loss)
Embedded derivatives gain (loss) at other companies
Other financials
Where this comes from
Reported directly by Medline, Inc. in its filing.
Tagged under the XBRL concept us-gaap:EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet.
The source filing: Medline, Inc.’s 10-K, filed February 25, 2026.
- Filed
- Feb 25, 2026, 4:51 PM EST
- Fiscal year
- FY2025
- Accession
- 0002046386-26-000009
| (in millions) | Year ended / December 31, 2025 | Year ended / December 31, 2024 | Year ended / December 31, 2023 |
|---|---|---|---|
| Depreciation and amortization | 1,011 | 977 | 951 |
| Stock-based compensation expense | 76 | 61 | 78 |
| Amortization of deferred financing costs | 59 | 57 | 80 |
| Embedded derivative on debt | (41) | — | — |
| Credit losses | 54 | 63 | 8 |
| Unrealized foreign exchange loss (gain), net | 68 | (10) | 3 |
| Amortization of inventory step-up | — | 25 | 90 |
| Loss on extinguishment of debt | 58 | 32 | — |
Item 8 - Financial Statements and Supplementary Data
FAQ
- What is Medline, Inc.'s embedded derivatives gain (loss)?
- Medline, Inc. (MDLN) reported embedded derivatives gain (loss) of $10.25M in Q4 2025.
- What does embedded derivatives gain (loss) mean?
- This metric captures the net change in fair value of derivative instruments that are embedded within other financial contracts. It reflects market-driven fluctuations in value that do not necessarily correlate with core operational performance.
Ask your AI about Medline, Inc.'s embedded derivatives gain (loss).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude